EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways

Sheila Almaraz Postigo, Juan Carlos Montero iD

Clinical Science · 2023

DOI: 10.1042/cs20220472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Science, 2023. Verfasst von Sheila Almaraz Postigo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Research of Salamanca (IBSAL), Instituto de Biología Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca) and CIBER…. Hauptthemen laut MEDLINE: Neuregulins, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Neuregulins (NRGs) are growth factors that bind and activate ErbB/HER receptor tyrosine kinases. Some reports have described an interplay between this ligand–receptor system and hormonal receptors in breast cancer. However, the mechanisms by which NRGs regulate hormonal receptor signaling have not been sufficiently described. Here, we show that in breast cancer cells the activation of NRG receptors down-regulated ERα through a double mechanism that included post-transcriptional and transcriptional effects. This regulation required the concerted participation of three signaling routes: the PI3K/AKT/mTOR, ERK1/2, and ERK5 pathways. Moreover, these three routes were also involved in the phosphorylation of ERα at serines 118 and 167, two residues implicated in resistance to endocrine therapies. On the other hand, NRGs conferred resistance to fulvestrant in breast cancer cells and this resistance could be reversed when the three pathways activated by NRGs were simultaneously inhibited. Our results indicate that estrogen receptor-positive (ER+) breast tumors that can have access to NRGs may be resistant to fulvestrant. This resistance could be overcome if strategies to target the three main pathways involved in the interplay between NRG receptors and ERα could be developed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuregulinsNeoplasmsFulvestrantEstrogen Receptor alphaPhosphatidylinositol 3-KinasesSignal TransductionDrug Resistance, NeoplasmCell Line, Tumor

Stichwörter der Autor:innen

Anti-estrogen therapyBreast cancerEstrogen receptorNeuregulin

Substanzen

NeuregulinsFulvestrantEstrogen Receptor alphaPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Institute of Biomedical Research of Salamanca (IBSAL), Instituto de Biología Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca) and CIBERONC, Salamanca, Spain.
  • Department of Pathology and IBSAL, University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain.

ORCID-Profile: Juan Carlos Montero

Zitieren

APA

Almaraz Postigo, S., & Montero, J. C. (2023). Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways. Clinical Science. https://doi.org/10.1042/cs20220472

Vancouver

Almaraz Postigo S, Montero JC. Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways. Clinical Science. 2023. doi:10.1042/cs20220472

BibTeX
@article{AlmarazPostigo2023,
  author = {Almaraz Postigo, Sheila and Montero, Juan Carlos},
  title = {Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways},
  journal = {Clinical Science},
  year = {2023},
  doi = {10.1042/cs20220472}
}
Kostenlos starten →